Salt-Active Nucleases (SAN)
Downstream Processing of Viral Vectors, Vaccines, Biologics
CommercialActive
Key Facts
Indication
Downstream Processing of Viral Vectors, Vaccines, Biologics
Phase
Commercial
Status
Active
Company
About ArcticZymes Technologies
ArcticZymes Technologies leverages its unique Arctic environment to discover and develop extremozymes—enzymes from extremophilic microorganisms—that function in non-standard conditions where conventional enzymes fail. With over 30 years of expertise, the company has pioneered industry breakthroughs like the first commercially available salt-active nuclease and COD UNG, targeting the high-growth markets of gene therapy, viral vector manufacturing, and molecular diagnostics. As a publicly traded company on the Oslo Stock Exchange, it focuses on providing GMP-grade enzymatic solutions to improve efficiency and reduce costs in biopharmaceutical production.
View full company profile